A previous post described an incredible price hike of a cancer-drug. Swiss firm Novartis increased the price of the drug six-fold. This drug is used in rare cancer cases and became available over twenty years ago. 533 more words
Tags » Novartis
Novartis' shocking cancer drug price hike
This morning, Dutch media reported on another case of a sickening price-hike by a pharmaceutical company. Swiss Novartis recently increased its price for a specific cancer drug six-fold. 377 more words
37th Annual J.P. Morgan HEALTHCARE CONFERENCE: #JPM2019 for Jan. 8, 2019; Opening Videos, Novartis expands Cell Therapies, January 7 - 10, 2019, Westin St. Francis Hotel | San Francisco, California
37th Annual J.P. Morgan HEALTHCARE CONFERENCE: #JPM2019 for Jan. 8, 2019; Opening Videos, Novartis expands Cell Therapies, January 7 – 10, 2019, Westin St. Francis Hotel | San Francisco, California… 798 more words
"I didn't know anyone at the World Health Organization who had himself vaccinated, including the director-general" - glaring conflicts of interest within WHO
Parading as protectors of our health! Follow the money again. (Watch video also at the link).
From aljazeera.com
Headquartered in Geneva, Switzerland, the WHO is now 7,000 employees strong, with six regional offices and 150 country offices around the world, and over 194 member states adhering to the regulations released by the organisation as per the United Nations system. 703 more words
Canadian Pot Firm Tilray Goes Global With Novartis Marijuana Deal
Tilray has signed a global partnership with a division of Swiss drug giant Novartis to develop and distribute its medical marijuana in legal jurisdictions around the world. 328 more words
Novartis reimagines medicine
Novartis’s recent acquisition streak is pivoting the company toward new treatments that bear little resemblance to traditional drugs.
The Swiss company has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumours for close-range radiotherapy. 543 more words
Novartis' OTC future comes into focus
Still ranked No.10 globally among OTC marketers, Novartis has nevertheless been gradually disinvesting from the consumer healthcare market in recent years, as it pursues its plan to “become a more focused innovative medicines company”, according to CEO, Vas Narasimhan. 388 more words
